Qianqian Chu
Research Subjects
Qianqian Chu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Bin Xiang
Peking University 4
10 shared publications - Chen Sang
Fudan University 3 Shanghai
10 shared publications - Guo-Ming Shi
Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China
10 shared publications - Jia Fan
Fudan University
10 shared publications - Jian Lin
Fudan University 2 Shanghai
10 shared publications - Jian Zhou
Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai 200032, China
10 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Data from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Metabolic reprogramming within the tumor microenvironment (TME) impairs antitumor immunity and compromises the efficacy of immunotherapy. Through multiomics-based metabolic subtyping in intrahepatic cholangiocarcinoma, we identified a subgroup with the worst prognosis that demonstrates significant enrichment in both cyclooxygenase/arachidonic acid (COX/AA) metabolism and KRAS mutations. Mechanistically, KRAS mutation–mediated NF-κB pathway activation upregulates CXCL5 expression, thereby recruiting CXCR2+ polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) into the TME. Concurrently, KRAS mutation drives prostaglandin E2 (PGE2) production in tumor cells, and PGE2, in turn, enhances AA uptake and COX-2 expression in PMN-MDSCs, establishing an amplifying loop between tumor cells and PMN-MDSCs that exacerbates PGE2 production. PGE2 accumulation potently suppresses the antitumor activity of CD8+ T cells via the prostaglandin E receptor 4 (EP4). Therapeutic targeting of the COX-2–PGE2–EP4 axis, combined with anti–PD-1 immunotherapy, demonstrates profound synergistic efficacy in both KRAS-mutant murine models and patient-derived tumor fragments harboring KRAS mutations. Significance:This work identifies a PGE2–COX-2 positive feedback loop between tumor cells and PMN-MDSCs that may serve as a therapeutic vulnerability for KRAS-mutant cholangiocarcinoma.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Metabolic reprogramming within the tumor microenvironment (TME) impairs antitumor immunity and compromises the efficacy of immunotherapy. Through multiomics-based metabolic subtyping in intrahepatic cholangiocarcinoma, we identified a subgroup with the worst prognosis that demonstrates significant enrichment in both cyclooxygenase/arachidonic acid (COX/AA) metabolism and KRAS mutations. Mechanistically, KRAS mutation–mediated NF-κB pathway activation upregulates CXCL5 expression, thereby recruiting CXCR2+ polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) into the TME. Concurrently, KRAS mutation drives prostaglandin E2 (PGE2) production in tumor cells, and PGE2, in turn, enhances AA uptake and COX-2 expression in PMN-MDSCs, establishing an amplifying loop between tumor cells and PMN-MDSCs that exacerbates PGE2 production. PGE2 accumulation potently suppresses the antitumor activity of CD8+ T cells via the prostaglandin E receptor 4 (EP4). Therapeutic targeting of the COX-2–PGE2–EP4 axis, combined with anti–PD-1 immunotherapy, demonstrates profound synergistic efficacy in both KRAS-mutant murine models and patient-derived tumor fragments harboring KRAS mutations. Significance:This work identifies a PGE2–COX-2 positive feedback loop between tumor cells and PMN-MDSCs that may serve as a therapeutic vulnerability for KRAS-mutant cholangiocarcinoma.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-S8 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Figures S1-S8 and their figure legends. Figure S1. Validation of metabolic subgroups and their related properties; Figure S2. Associations between PMN-MDSC infiltration and COX/AA metabolism; Figure S3. KRAS mutation promotes an immunosuppressive TME in iCCA; Figure S4. KRAS mutation activates NF-κB signaling to promote chemotaxis of neutrophils through CXCL5-CXCR2 axis; Figure S5. AA supplementation promotes the progression of KRAS MUT iCCA; Figure S6. PMN-MDSC-derived PGE2 suppresses CD8+ T cells via EP4 to circumvent ICB efficacy; Figure S7. The COX/AA metabolism serves as a predictive biomarker for patient response to ICB therapy; Figure S8. Graphic abstract of this study.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-S8 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Figures S1-S8 and their figure legends. Figure S1. Validation of metabolic subgroups and their related properties; Figure S2. Associations between PMN-MDSC infiltration and COX/AA metabolism; Figure S3. KRAS mutation promotes an immunosuppressive TME in iCCA; Figure S4. KRAS mutation activates NF-κB signaling to promote chemotaxis of neutrophils through CXCL5-CXCR2 axis; Figure S5. AA supplementation promotes the progression of KRAS MUT iCCA; Figure S6. PMN-MDSC-derived PGE2 suppresses CD8+ T cells via EP4 to circumvent ICB efficacy; Figure S7. The COX/AA metabolism serves as a predictive biomarker for patient response to ICB therapy; Figure S8. Graphic abstract of this study.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Subgroup-associated characteristics and qRT-PCR primers.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Subgroup-associated characteristics and qRT-PCR primers.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Differences of the metabolic pathways among indicated cell subsets.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Differences of the metabolic pathways among indicated cell subsets.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Differential gene expression in AY vs. AYK tumor-derived PMN-MDSCs and related sequences.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Differential gene expression in AY vs. AYK tumor-derived PMN-MDSCs and related sequences.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Expression of chemokines and chemokine receptors in KRAS MUT versus KRAS WT samples.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Expression of chemokines and chemokine receptors in KRAS MUT versus KRAS WT samples.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
The expression variations of COX/AA metabolic pathway genes.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
The expression variations of COX/AA metabolic pathway genes.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Supplementary Table 6 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Supplementary Table 6 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Full sample sizes (n), exact P values, and effect sizes are presented across the figures.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Full sample sizes (n), exact P values, and effect sizes are presented across the figures.
- 8 April 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (9) , 1903-1923
Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T cells in KRAS-Mutant Cholangiocarcinoma
Metabolic reprogramming within the tumor microenvironment impairs antitumor immunity and compromises the efficacy of immunotherapy. Through multi-omics-based metabolic subtyping in intrahepatic cholangiocarcinoma (iCCA), we identified a subgroup with the worst prognosis that demonstrates significant enrichment in both Cyclooxygenase/Arachidonic acid (COX/AA) metabolism and KRAS mutations. Mechanistically, KRAS mutation-mediated NF-κB pathway activation upregulates CXCL5 expression, thereby recruiting CXCR2+ polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) into the tumor microenvironment. Concurrently, KRAS mutation drives prostaglandin E2 (PGE2) production in tumor cells, and PGE2 in turn enhances arachidonic acid uptake and COX-2 expression in PMN-MDSCs, establishing an amplifying loop between tumor cells and PMN-MDSCs that exacerbates PGE2 production. PGE2 accumulation potently suppresses the antitumor activity of CD8+ T cells via prostaglandin E receptor 4 (EP4). Therapeutic targeting of the COX-2–PGE2–EP4 axis, combined with anti-PD-1 immunotherapy, demonstrates profound synergistic efficacy in both KRAS-mutant murine models and patient-derived tumor fragments harboring KRAS mutations.
- 8 April 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (9) , 1903-1923
Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T cells in KRAS-Mutant Cholangiocarcinoma
Metabolic reprogramming within the tumor microenvironment impairs antitumor immunity and compromises the efficacy of immunotherapy. Through multi-omics-based metabolic subtyping in intrahepatic cholangiocarcinoma (iCCA), we identified a subgroup with the worst prognosis that demonstrates significant enrichment in both Cyclooxygenase/Arachidonic acid (COX/AA) metabolism and KRAS mutations. Mechanistically, KRAS mutation-mediated NF-κB pathway activation upregulates CXCL5 expression, thereby recruiting CXCR2+ polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) into the tumor microenvironment. Concurrently, KRAS mutation drives prostaglandin E2 (PGE2) production in tumor cells, and PGE2 in turn enhances arachidonic acid uptake and COX-2 expression in PMN-MDSCs, establishing an amplifying loop between tumor cells and PMN-MDSCs that exacerbates PGE2 production. PGE2 accumulation potently suppresses the antitumor activity of CD8+ T cells via prostaglandin E receptor 4 (EP4). Therapeutic targeting of the COX-2–PGE2–EP4 axis, combined with anti-PD-1 immunotherapy, demonstrates profound synergistic efficacy in both KRAS-mutant murine models and patient-derived tumor fragments harboring KRAS mutations.